Get the Stockscreener App
129.44
0.92%
1.3265
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $129.44, with a volume of 1.71M.
It is up +0.92% in the last 24 hours and up +1.93% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
See More
Previous Close:
$128.11
Open:
$127.46
24h Volume:
1.71M
Relative Volume:
0.29
Market Cap:
$224.89B
Revenue:
$43.84B
Net Income/Loss:
$13.90B
P/E Ratio:
16.24
EPS:
7.9725
Net Cash Flow:
$6.92B
1W Performance:
-0.57%
1M Performance:
+1.93%
6M Performance:
-1.53%
1Y Performance:
+9.79%
1-Day Range:
$126.72
$129.52
1-Week Range:
$122.09
$132.03
52-Week Range:
$110.86
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
129.33 | 222.77B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
97.58 | 143.62B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
371.62 | 140.84B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
102.78 | 129.80B | 34.76B | 4.79B | 5.21B | 3.7049 |
|
EW
Edwards Lifesciences Corp
|
85.09 | 49.40B | 5.88B | 1.34B | 799.60M | 2.3489 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Jefferies cuts Exact Sciences to 'hold' after Abbott acquisition - TradingView
Is Weakness In Abbott Laboratories (NYSE:ABT) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? - Yahoo Finance
Jefferies downgrades Exact Sciences stock to Hold after Abbott acquisition - Investing.com
Jim Cramer on Abbott: “I Think It’s a Terrific Time to Do Some Buying” - MSN
Jim Cramer on Abbott: "I Think It's a Terrific Time to Do Some Buying" - Finviz
Exact Sciences (EXAS) Shares Surge on Abbott Acquisition Deal - GuruFocus
Notable healthcare headlines for the week: Abbott, Medtronic, Merck and J&J in focus - MSN
Abbott’s (ABT) Exact Sciences Deal is “Very, Very Important,” Says Jim Cramer - MSN
AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know - Yahoo Finance
Abbott acquires cancer diagnostic company Exact Sciences for $21B - HealthExec
William Blair Remains a Buy on Abbott Laboratories (ABT) - The Globe and Mail
ABTAbbott Laboratories Stock Price and Quote - Finviz
Abbott Laboratories Stock Price Forecast: Where Analysts See the Stock Going by 2027 - TIKR.com
Abbott Labs stock to acquire Exact Sciences for $21 billion By Investing.com - Investing.com Nigeria
Deal Dispatch: Abbott, TPG And Lonza Make Major Moves, M&M Custard And New Fortress Energy Struggle - Benzinga
Abbott Laboratories: Not Passing The Test After Buying Test Maker Exact Sciences (ABT) - Seeking Alpha
Abbott to acquire Exact Sciences in $21 billion deal, aiming to lead in fast-growing cancer diagnostics market - Medical Economics
Abbott’s $21B Exact Sciences buy reveals future strategy - MedTech Dive
Abbott Laboratories to acquire Exact Sciences for $23B in largest-ever diagnostics deal - The Business Journals
Abbott Laboratories Acquires Exact Sciences In $23 Billion Deal - Patch
Abbott Labs stock to acquire Exact Sciences for $21 billion - Investing.com India
Abbott Labs stock gains as UBS reiterates Buy rating on Exact Sciences deal - Investing.com India
Abbott Laboratories’ Strategic Acquisition of Exact Sciences: Enhancing Diagnostics Business and Long-term Growth Prospects - TipRanks
Top 2 Healthcare Stocks Every New Investor Should Know - The Motley Fool
Street View: Brokerages downgrade Exact Sciences following acquisition by Abbott - TradingView
Abbott’s colon-screening deal stinks financially - TradingView
Barclays Sticks to Its Buy Rating for Abbott Laboratories (ABT) - The Globe and Mail
Abbott Breaks into Lucrative Cancer Screening Market with $21 Billion Exact Sciences Purchase - The Daily Upside
Abbott's $21B splurge signals long-awaited dealmaking thaw in health tech - Crain's Chicago Business
Abbott is buying Exact Sciences. Here’s why - Modern Healthcare
Madison's Exact Sciences purchased by Abbott Laboratories, Ancient canoe is the region's oldest - WPR
Abbott to acquire all outstanding shares in Exact Sciences - Medical Device Network
Why Abbott Laboratories (ABL) stock could be next leaderEarnings Beat & Safe Entry Zone Identification - newser.com
Abbott Laboratories’ Strategic Acquisition of Exact Sciences: Enhancing Diagnostics and Driving Long-term Growth - TipRanks
Abbott Eyes Exact Sciences: Market Stir - StocksToTrade
Abbott Laboratories’ Strategic Acquisition of Exact Sciences Bolsters Diagnostics Growth and Expands Cancer Screening Portfolio - TipRanks
Abbott to Acquire Exact Sciences in a $21 Billion Deal, Boosting Cancer Diagnostics Push - NAI500
Exact Sciences, Leader in Cancer Screening and Genomics Testing, to Join Abbott Laboratories in 2026 - Morningstar
Abbott bolsters diagnostics portfolio with up to $23 billion buyout of Exact Sciences - WTAQ
Why the Stock Price of This Cancer Screening Company Soared 17% Thursday - Investopedia
Abbott Laboratories $23B purchase of Cologuard maker Exact Sciences could have Arizona implications - The Business Journals
Abbott Inks 2025’s Largest Bridge Loan to Fund Acquisition - Bloomberg.com
Abbott Labs to acquire Madison’s Exact Sciences in $23 billion deal - Wisconsin State Journal
Abbott to buy Madison-based Exact Sciences in deal valued at up to $23 billion - Milwaukee Journal Sentinel
Exact Sciences Catapults On $23 Billion Abbott Labs Buyout - Investor's Business Daily
Abbott Laboratories to acquire Exact Sciences in deal worth up to $23B - The Business Journals
Abbott Laboratories announces $21 billion deal to buy Cologuard-maker Exact Sciences - Yahoo Finance
Abbott Laboratories, Exact Sciences make $23B deal with Bay Area implicationsSan Francisco Business Times - The Business Journals
FDA expands urgent baby formula recall to all products made by one manufacturer - TheStreet
Is it too late to buy Exact Sciences stock after Abbott’s $21B deal? - TradingView
Abbott To Complete $21B M&A Deal For Exact SciencesWhat Investors Should Know - Seeking Alpha
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):